Your online consultation

Start by checking your eligibility, then complete a fast, secure online consultation. A clinician reviews everything and, if you’re approved, your treatment plan begins.



Start by checking your eligibility, then complete a fast, secure online consultation. A clinician reviews everything and, if you’re approved, your treatment plan begins.

You’ve started treatment, and you’re beginning to see results. You’re building healthier habits, feeling more confident, and noticing wins outside the scales. Think looser clothing and more energy for the things you love.

You’ve settled into a routine that supports real, lasting change. The habits you’ve built now help keep the weight off for good, and our clinicians and weight loss specialists continue to guide you every step of the way.
Calculate your Body Mass Index to understand your weight category

We're committed to your safety and wellbeing

All clincal assessments and medication prescribed is via myBMIs clinical team, including James O’Loan (GPhC: 2084549), Lou Humphreys (GPhC: 2049466) John Campbell (GPhC: 2069835) Ian Budd (GPhC: 2037876) Celina Mark (GPhC: 2216421) and Ayesha Bashir (GPhC: 2209645) who are all General Pharmaceutical Council (GPhC) registered, ensuring full compliance with professional requirements for GPhC prescribing. myBMI is also regulated via its partnership with its dispensing pharmacy Innox Trading Ltd, (t/a Chemist4U), which is registered with the GPhC under number 9012464.
It’s natural to have questions, and we’re here to keep things straightforward so you can stay focused on your journey.
Get supportWegovy tablets are an oral semaglutide medication used to support weight loss by helping you regulate your appetite and food intake. They are designed for people who want medical support without injections.
While Wegovy tablets have been approved in the US, they need to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA) before they can be prescribed in the UK. Experts believe they may be available by late 2026, or early 2027.
The active ingredient is semaglutide, a GLP-1 receptor agonist that mimics hormones involved in appetite control.
Semaglutide, whether in tablets or an injectable pen, works by:
During the 2025 OASIS 4 trial looking at the effects of oral semaglutide on people with overweight or obesity, it was shown that patients on average lost 14% of their starting body weight while on Wegovy tablets.
This compares to the average weight loss of 21% seen on Wegovy injections.
However, overall weight loss varies depending on:
As Wegovy tablets aren’t yet approved in the UK, we don’t know the eligibility criteria for the treatment. However, if they are approved, eligibility will be assessed by a qualified clinician to ensure safety and suitability.
What are the available doses of Wegovy tablets?
In the US, the available doses of Wegovy tablets are as follows:
As with Wegovy injections, patients are recommended to gradually increase their dose over time, so you can get use to the medication.
These doses may change in the UK once the treatment is approved by the MHRA.
We currently don’t know how much Wegovy tablets will cost in the UK. The price of the treatment will depend on the price Novo Nordisk sets for the UK market, how available they are, and the dose you end up taking.
In the US, Wegovy tablets are approved to be taken once daily. The manufacturer states they need to be taken on an empty stomach after waking up, alongside a sip of water.
The manufacturere recommends that patients should then wait 30 minutes before eating, drinking, or taking any other oral medications.
What happens if you miss a dose?
The manufacture states that if a dose of Wegovy tablets is missed, the dose should be skipped, and to resume the scheduled dose the next day.
Common side effects noted in clinical trials included:
The manufacturer currently advises patients to seek urgent advice if they experience:
No. Rybelsus is an oral semaglutide medication approved for type 2 diabetes, not specifically for weight loss.
While both contain semaglutide, they have different uses in clinical trials, different maximum doses, and Wegovy is not currently licensed in the UK.
Wegovy tablets are not yet available in the UK. They first need to be approved by the MHRA.
In clinical trials, Wegovy tablets worked best when combined with lifestyle changes. Treatment can help reduce appetite, but long-term success comes from sustainable habits.
Clinical trials data showed that some people notice reduced appetite within weeks of starting Wegovy tablets, but meaningful weight loss typically developed over several months.
“If Wegovy tablets (semaglutide tablets) become available in the UK, they could offer a potential needle-free approach to weight loss, helping patients manage their appetites and support healthier habits.”
“However, to ensure the treatment is safe and suitable for the UK market, it first needs to be approved by the MHRA.”
Ayesha Bashir, weight loss expert at myBMI

Here's how our service works in 3 simple steps:

Start by completing a quick online consultation. This helps our clinicians understand your health and decide whether treatment is safe and suitable for you. As part of this, you’ll be asked to submit photos to confirm your identity and your weight. These will only ever be viewed by your clinician.
After your consultation, one of our clinicians will carefully assess whether treatment is right for you. If approved, they’ll issue a prescription and your medication will be delivered straight to your door with our discreet, tracked, and signed-for service.
Your journey doesn’t stop with your delivery. Our clinicians are here to support you every step of the way. You can check in anytime through your account for advice, and we’ll review your progress regularly to help you stay on track and achieve lasting results. You’ll also be invited to join our exclusive support group, giving you access to expert medical guidance and tailored content designed to keep you motivated.